ArticleJournal of current glaucoma practice
Effect of Sub-Tenon's Triamcinolone on Hypertensive Phase and Clinical Outcomes Following Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma Patients.
Article in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effect of sub-Tenon's triamcinolone acetonide (TA) on the hypertensive phase (HP) and postoperative outcomes in patients with neovascular glaucoma (NVG) after Ahmed glaucoma valve (AGV) surgery. Methods: We conducted a retrospective review of 112 NVG patients (58 TA, 54 non-TA) who underwent AGV implantation with a 6-month follow-up. HP was defined as intraocular pressure (IOP) > 21 mm Hg within the first 3 months. Primary outcomes included IOP and HP occurrence. Secondary outcomes included complications, number of glaucoma drops, surgical failure, and visual acuity (VA). Results: Non-TA patients were significantly more likely to develop HP (70 vs 50%, Conclusion: Sub-Tenon's TA reduces the risk of HP and short-term IOP spikes in NVG patients undergoing AGV implantation but does not improve long-term IOP regulation, visual outcomes, or surgical success. Clinical significance: Reducing HP may help prevent early postoperative complications, improving short-term management of NVG patients receiving AGV implants. How to cite this article: Hong AT, Kishi SH, Humayun L,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.